These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1204 related items for PubMed ID: 27731896

  • 1. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB, Munjal S, Buse DC, Fanning KM, Bennett A, Reed ML.
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [Abstract] [Full Text] [Related]

  • 2. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB, Munjal S, Buse DC, Bennett A, Fanning KM, Burstein R, Reed ML.
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [Abstract] [Full Text] [Related]

  • 3. Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine.
    Ezzati A, Fanning KM, Reed ML, Lipton RB.
    Headache; 2023 Mar; 63(3):342-352. PubMed ID: 36748728
    [Abstract] [Full Text] [Related]

  • 4. Acute treatment optimization in episodic and chronic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Serrano D, Buse DC, Manack Adams A, Reed ML, Lipton RB.
    Headache; 2015 Apr; 55(4):502-18. PubMed ID: 25881676
    [Abstract] [Full Text] [Related]

  • 5. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Ezzati A, Buse DC, Fanning KM, Reed ML, Martin VT, Lipton RB.
    Clin Neurol Neurosurg; 2022 Dec; 223():107511. PubMed ID: 36395587
    [Abstract] [Full Text] [Related]

  • 6. Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
    Ezzati A, Fanning KM, Buse DC, Pavlovic JM, Armand CE, Reed ML, Martin VT, Lipton RB.
    Headache; 2022 Jun; 62(6):755-765. PubMed ID: 35546653
    [Abstract] [Full Text] [Related]

  • 7. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R.
    Headache; 2012 Jan; 52(1):3-17. PubMed ID: 22106869
    [Abstract] [Full Text] [Related]

  • 8. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK, Buse DC, Bigal ME, Serrano D, Lipton RB.
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [Abstract] [Full Text] [Related]

  • 9. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC, Serrano D, Reed ML, Kori SH, Cunanan CM, Adams AM, Lipton RB.
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [Abstract] [Full Text] [Related]

  • 10. Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.
    Reed ML, Fanning KM, Serrano D, Buse DC, Lipton RB.
    Headache; 2015 Jan; 55(1):76-87. PubMed ID: 25250833
    [Abstract] [Full Text] [Related]

  • 11. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features.
    Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC.
    Headache; 2013 Jan; 53(1):81-92. PubMed ID: 23078241
    [Abstract] [Full Text] [Related]

  • 12. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
    Lipton RB, Munjal S, Buse DC, Alam A, Fanning KM, Reed ML, Schwedt TJ, Dodick DW.
    Headache; 2019 Sep; 59(8):1310-1323. PubMed ID: 31410844
    [Abstract] [Full Text] [Related]

  • 13. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB.
    J Neurol Sci; 2013 Mar 15; 326(1-2):10-7. PubMed ID: 23394974
    [Abstract] [Full Text] [Related]

  • 14. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB, Buse DC, Serrano D, Holland S, Reed ML.
    Headache; 2013 Sep 15; 53(8):1300-11. PubMed ID: 23879870
    [Abstract] [Full Text] [Related]

  • 15. A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability.
    Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML.
    Headache; 2016 Sep 15; 56(8):1280-9. PubMed ID: 27349336
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
    Schwedt TJ, Alam A, Reed ML, Fanning KM, Munjal S, Buse DC, Dodick DW, Lipton RB.
    J Headache Pain; 2018 May 24; 19(1):38. PubMed ID: 29797100
    [Abstract] [Full Text] [Related]

  • 17. Asthma is a risk factor for new onset chronic migraine: Results from the American migraine prevalence and prevention study.
    Martin VT, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB.
    Headache; 2016 Jan 24; 56(1):118-31. PubMed ID: 26581563
    [Abstract] [Full Text] [Related]

  • 18. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB, Serrano D, Pavlovic JM, Manack AN, Reed ML, Turkel CC, Buse DC.
    Headache; 2014 May 24; 54(5):830-49. PubMed ID: 24527745
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB.
    Headache; 2017 Jan 24; 57(1):31-44. PubMed ID: 27861837
    [Abstract] [Full Text] [Related]

  • 20. Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences.
    Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML, Schwedt TJ, Dodick DW.
    Headache; 2018 Oct 24; 58(9):1408-1426. PubMed ID: 30341895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.